The systemic autoinflammatory disorders for dermatologists. Part 2: disease examples

J. Oldham1 and H. J. Lachmann1

1Portsmouth Hospitals NHS Trust, National Amyloidosis Centre, UCL Division of Medicine and Royal Free London NHS Foundation Trust, Portsmouth, Hampshire, UK

doi:10.1111/ced.14251

Summary

The systemic autoinflammatory disorders (SAIDS) or periodic fever syndromes are disorders of innate immunity, which can be inherited or acquired. They are almost all very rare and easily overlooked; typically, patients will have seen multiple specialties prior to diagnosis, so a high level of clinical suspicion is key. It is important to note that these are ‘high-value’ diagnoses as the majority of these syndromes can be very effectively controlled, dramatically improving quality of life and providing protection against the development of irreversible complications such as AA amyloidosis. In Part 1 of this review, we took an overview of SAIDS and described the common features; in this article, we take a more in-depth look at the better recognized or more dermatologically relevant conditions.

Introduction

The systemic autoinflammatory disorders (SAIDS) were introduced in Part 1 of this article. Some of the more common examples presenting to a dermatologist will be explored further below.

Cryopyrin-associated periodic syndromes

Cryopyrin-associated periodic syndromes (CAPS) was first described as a form of cold-induced rash in 1945, and the group is now recognized as a spectrum of clinical conditions ranging from mild familial cold urticaria to severe neonatal-onset multisystem inflammatory disease or chronic infantile neurological, cutaneous and articular syndrome. The common underlying pathology is a gain of function mutation in a key component of the interleukin (IL)-1 inflammasome.1 CAPS are inherited in an autosomal dominant fashion, although a substantial proportion of patients have somatic mutations.2

CAPS affect an estimated one to three per million in the UK with no ethnic predisposition. Dysregulated production of IL-1 results in constitutional upset with febrile symptoms of myalgia, chills and night sweats, as well as severe fatigue, headache, ocular inflammation (resulting in red eyes) and a characteristic urticarial rash.3 Many patients have daily symptoms in a diurnal pattern, with symptoms worsening over the course of the day.2 This rash is distributed equally over arms, trunk or legs. The lesions present as erythematous macules or slightly raised papules/plaques. They are neither oedematous nor annular in nature, although they may have a peripheral halo of vasoconstriction. Individual lesions resolve within 24 h (Fig. 1).4 If not treated, irreversible damage may occur, which can include sensorineural hearing loss, vision loss, skeletal deformities, cognitive disability and systemic AA amyloidosis.5

Treatment has been revolutionized by drugs providing long-term IL-1 blockade.5 Anakinra, canakinumab and rilonacept are all given subcutaneously, and have been shown to alleviate symptoms with dramatic
improvements. There is now excellent safety data for over 15 years, with the only reported adverse effects being a modest increase in infections and development of mild neutropenia.

Familial Mediterranean fever

Familial Mediterranean fever (FMF) is associated with mutations in the Mediterranean fever gene (MEFV), which encodes pyrin. In the majority of patients, this is inherited in an autosomal recessive manner, although up to 20% have only one identified variant, and a few mutations are recognized to cause dominant inheritance. Mutations appear to result in decreased phosphorylation of pyrin and gain of function, resulting in increased activation of the pyrin inflammasome and release of IL-1β.

Familial Mediterranean fever is the most common of the inherited autoinflammatory diseases by far; it occurs worldwide but is most frequent in Eastern Mediterranean populations. Typical onset is early in life, with 50% having their first attack prior to 10 years of age and 90% prior to 20 years. Symptoms include recurring attacks of fever and extremely painful serositis lasting 12–72 h. Peritonitic abdominal pains occur in 80% of attacks (40% of patients undergo laparoscopy prior to diagnosis), and other common symptoms are pleuritic chest pain and nonerosive arthritis. The skin manifestation is an erysipelas-like erythema, usually between the knee and the dorsum of the foot, which is commoner in children and associated with the commonest and most severe mutation, M694V (Fig. 2). Untreated FMF was historically associated with a very poor outcome, and 60% developed end stage renal failure due to AA amyloidosis.

Most patients find that nonsteroidal anti-inflammatory drugs (NSAIDs) provide better symptom relief than other analgesics in acute attacks but the aim of treatment is to prioritize prophylaxis with lifelong colchicine, and long-term follow-up studies have provided reassuring safety data, including in pregnancy and breastfeeding. With appropriate treatment, most patients will be symptom-free and the risk of amyloidosis disappears. In resistant cases, IL-1 inhibitors have been shown to be effective. The European League Against Rheumatism published guidelines in 2015 with detailed recommendations on the management of FMF.

Tumour necrosis factor receptor-associated periodic syndrome

Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autosomal dominant
disease caused by mutations in the gene for TNF receptor 1. The exact pathogenesis remains unclear, although it seems the variant protein does not reach the cell membrane.\(^\text{17}\)

TRAPS has an estimated prevalence of 12 per million in the UK. Median age at presentation is 7 years, with initially episodic attacks.\(^\text{18}\) These attacks can be discrete or become near-continuous, and are often prolonged, lasting several weeks. They are accompanied by fever (88%), abdominal pain (74%), rash (63%), eye manifestations (43%), pleuritic pain (32%), headache (28%) and lymphadenopathy (14%).\(^\text{18}\) The disease-associated rashes can be nonspecific and pleomorphic. Periorbital rash (Fig. 3) and oedema and migratory erythematous plaques overlying sites of myalgia are most commonly described, but serpiginous and urticarial rashes can also occur (Fig. 4). There is an acute phase response (which can be very elevated) and leucocytosis on blood tests. Untreated, TRAPS has a 25% risk of AA amyloidosis.\(^\text{19}\)

An acute attack can be helped by NSAIDs (for symptoms) or steroids at 0.5–1 mg/kg for 5–10 days (to shorten attack). In more severe disease, IL-1 blockade is highly effective.\(^\text{20,21}\)

**Mevalonate kinase deficiency**

Mevalonate kinase deficiency (MKD) is a very rare autosomal recessive disease caused by a hypomorphic mutation in the mevalonate kinase gene (MVK). The MVK protein plays a role in the biosynthetic pathway that produces cholesterol and nonsterol isoprenoids. A proposed mechanism is reduced synthesis of isoprenoids, which in turn reduces prenylation of RoR-\text{etGTPases} and disrupts their role in cytoskeletal regulation and vesicle trafficking, leading to

Figure 3 (a, b) Typical presentation of tumour necrosis factor receptor-associated periodic syndrome. Courtesy of Helen Lachmann, National Amyloidosis Centre.

Figure 4 Typical presentations of (a) mevalonate kinase deficiency and (b) Schnitzler syndrome. Courtesy of Helen Lachmann, National Amyloidosis Centre.
overactivation of the pyrin inflammasome with consequent production of IL-1β.22,23

Mevalonate kinase deficiency has two clinical phenotypes. Total enzyme deficiency results in the metabolic disorder mevalonic aciduria, which is lethal unless early bone marrow transplantation is performed. Currently there are around 300 reported patients with the milder periodic fever syndrome variant, mostly from northwestern Europe, although the disease occurs worldwide.

Onset of MKD characteristically occurs in the first 6 months of life with recurrent episodes of fever lasting 3–7 days. Typical symptoms are gastrointestinal upset (98%), lymphadenopathy (90%), arthralgia (71%), oral aphthae (60%), maculopapular rash (39%) (Fig 4a), headache (38%) and eye inflammation (15%).24 Long-term complications include AA amyloidosis, severe or recurrent infections, abdominal adhesions and joint contractures.

Treatment is difficult, but IL-1 blockade appears promising.20 Patients who are resistant to this treatment sometimes respond to IL-6 blockade.25

### Table 1 Summary of the key difference between the autoinflammatory conditions discussed

| Autoinflammatory Disease | Ethnicity | Typical presentation | Typical dermatology findings | Normal treatment |
|-------------------------|-----------|----------------------|-----------------------------|-----------------|
| CAPS                    | No        | predisposition       | Myalgia, chills, night sweats, ocular inflammation, diurnal symptoms worsening over day | Urticarial rash affecting trunk and limbs |
| IL-1 blockade           |           |                      |                             |                 |
| FMF                     | Eastern   | Mediterranean        | Fever, extremely painful serositis | Erysipelas-like erythema between knee and foot |
| NSAIDs as acute treatment; lifelong colchicine |          |                      |                             |                 |
| TRAPS                   | Possibly Scottish/Irish | Discrete or continuous. Abdominal pain, fevers, ocular inflammation, pleuritic pain | Pleomorphic. Periorbital rash and oedema. Erythematous plaques overlying myalgia. | Acute attack: NSAIDs/steroids. May benefit from IL-1 blockade |
| MKD                     | Northwestern European | Gl upset, lymphadenopathy, arthralgia, headache, ocular inflammation | Maculopapular Rash | IL-1 blockade |
| SS                      | No        | predisposition       | Acquired: onset in 50s. Fever, arthralgia, bone pain, lymphadenopathy | Urticarial rash |
| IL-1 blockade DIRA      | No        | predisposition       | Neonatal onset. Osteitis | Pustular rash |
| IL-1 blockade DITRA     | No        | predisposition       | Childhood to 60s. Fever | Pustular rash |

CAPS, Cryopyrin-associated periodic syndromes; DIRA, deficiency of the interleukin-1 receptor antagonist; DITRA, deficiency of the interleukin-36 receptor antagonist; FMF, familial Mediterranean fever; GI, gastrointestinal; IL, interleukin; MKD, mevalonate kinase deficiency; NSAID, nonsteroidal anti-inflammatory drug; SS, Schnitzler syndrome; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

### Schnitzler syndrome
Schnitzler syndrome (SS) was first reported in 1974. The disease process appears to be mediated by a monoclonal immunoglobulin (IgM), although the mechanism is unclear.

The median age of onset of SS is 51 years. There is no associated family history and the condition is slightly more prevalent in men. Diagnosis is based on the the Strasbourg Diagnostic Criteria and typical features include fever, a chronic urticarial-like rash similar to CAPS, arthralgia, bone pain, and lymphadenopathy or hepatosplenomegaly (Fig 4b).26,27 Around 20% of patients eventually progress to overt plasma cell malignancy.28 Treatment with IL-1 blockage seems to have excellent long-term response.29–31

### Deficiency of the interleukin-1 and interleukin-36 receptor antagonists
Deficiency of the IL-1 receptor antagonist (DIRA) is a rare autosomal recessive disease caused by a mutation
of the IL1RN gene, resulting in absences or dysfunction of the IL-1 receptor antagonist and thus unopposed action at the IL-1 receptors. DIRA is characterized by a neonatal onset pustular rash, multifocal osteitis and periarticular soft-tissue swelling. It can be treated successfully with anakinra, which replaces the genetic deficiency.32,33

Another condition, deficiency of the IL-36 receptor antagonist (DITRA) is also an autosomal recessive disease. DITRA is caused by a mutation on the IL36RN gene resulting in loss of the IL-36 receptor antagonist.34 Onset of DITRA is typically from childhood to the sixth decade of life, and may be precipitated by stress, pregnancy or drugs. It is characterized by a recurrent generalized sterile pustular rash accompanied by neutrophilia and fever. There are case reports indicating that patients with DITRA also benefit from anakinra.35-37

Undifferentiated syndromes

As previously mentioned many patients with suspected SAIDS do not fit into one of the aforementioned or other known syndromes (Table 1 summarizes these key features). They are considered to have undifferentiated disease and ruling out other differentials is included in Part 1. In addition, many do not have any identified autoinflammatory genetic abnormality. However, these patients may still have a long-term risk of amyloidosis. Treatment with colchicine, corticosteroids or biologics may therefore be considered if there is evidence of persistent inflammation and can be guided by a specialist.

Conclusion

The SAIDS are a collection of diseases that, although rare, are high-value diagnoses with the potential for highly effective, life-changing treatment. Most have some form of skin manifestation as a primary clinical feature, and therefore are important diseases for a dermatologist to bear in mind. Newer drugs have the potential for life-changing therapy.

Learning points

• SAIDS are disorders of innate immunity that can by inherited or aquired.
• Key features are recurrent, generalized inflammation.
• Many have dermatological features.
• If untreated, some of the conditions can progress to more severe conditions, including AA amyloidosis.
• Treatments include NSAIDs, colchichine, steroids and biologics.
• Diseases resulting from mutations in IL-associated genes can benefit from IL inhibitors.

References

1 Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 11: 1029–36.
2 Rowczenio DM, Melo Gomes S, Aróstegui JI et al. Late-onset cryopyrin-associated periodic syndromes caused by somatic NLRP3 mosaicism—UK single center experience. Front Immunol 2017; 8: 1410.
3 Levy R, Gérard L, Kueummerle-Deschner J et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 2015; 74: 2043–9.
4 Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009; 88: 23–31.
5 Hawkins PN, Lachmann HJ, Aganna E et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607–12.
6 Kullenberg T, Löfqvist M, Leinonen M et al. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford) 2016; 55: 1499–506.
7 Hoffman HM, Throne ML, Amar NJ et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443–52.
8 Lachmann HJK-PI, Kueummerle-Deschner JB, Leslie KS et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416–25.
9 French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25–31.
10 Stoffels M, Saperl A, Simon A et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Am Rheum Dis 2014; 73: 455–61.
11 Park YH, Wood G, Kastner DL et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 2016; 17: 914–21.
The systemic autoinflammatory disorders. Part 1 • J. Oldham and H. J. Lachmann

12 Lachmann HJ, Sengul B, Yavuzsen TU et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. *Rheumatology (Oxford)* 2006; 45: 746–50.

13 Tunca M, Akar S, Oen F et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. *Medicine* 2005; 84: 1–11.

14 Ben-Zvi I, Kukuy O, Giat E et al. Phenotype and genotype of mevalonate kinase deficiency. *Rheumatology (Oxford)* 2017; 66: 140–8.

15 Ozen S, Demirkaya E, Erer B et al. EULAR recommendations for the management of familial Mediterranean fever. *Ann Rheum Dis* 2016; 75: 644–51.

16 Ben-Zvi I, Kukuy O, Giat E et al. Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheumatol* 2017; 69: 854–62.

17 Bachetti T, Ceccherini I. Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases. *J Mol Med (Berl)* 2014; 92: 583–94.

18 Lachmann HJ, Papa R, Gerhold K et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. *Ann Rheum Dis* 2014; 71: 2035–43.

19 Lane T, Loeffler JM, Rowczenio DM et al. AA amyloidosis complicating the hereditary periodic fever syndromes. *Arthritis Rheum* 2013; 65: 1116–21.

20 Ter Haar N, Lachmann H, Özcan S et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. *Ann Rheum Dis* 2013; 72: 678–85.

21 De Benedetti F, Gattorno M, Anton J et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. *N Engl J Med* 2018; 378: 1908–19.

22 Munoz MA, Jurczyk J, Mehr S et al. Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency. *J Allergy Clin Immunol* 2017; 140: 873–5.

23 van der Burgh R, Pervolaraki K, Turkenburg M et al. Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity. *J Biol Chem* 2014; 289: 27757–65.

24 Ter Haar NM, Jeyaratnam J, Lachmann HJ et al. The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever registry. *Arthritis Rheum* 2016; 68: 821–30.

25 Lane T, Gillmore JD, Wechalekar AD et al. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. *Clin Exp Rheum* 2015; 33(Suppl): S46–53.

26 Simon A, Asli B, Braun-Falco M et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. *Allergy* 2013; 68: 562–8.

27 Lipsker D. The Schnitzler syndrome. *Orphanet J Rare Dis* 2010; 5: 38.

28 de Koning HD, Bodar EJ, van der Meer JW et al. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. *Semin Arthritis Rheum* 2007; 37: 137–48.

29 Krause K, Weller K, Steffaniak R et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. *Allergy* 2012; 67: 943–50.

30 de Koning HD, Schalkwijk J, van der Meer JW et al. Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome. *J Allergy Clin Immunol* 2011; 128: 1352–4.

31 de Koning HD, Bodar EJ, Simon A et al. Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome. *Ann Rheum Dis* 2006; 65: 542–4.

32 Aksentijevich I, Masters SL, Ferguson PJ et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. *N Engl J Med* 2009; 360: 2426–37.

33 Reddy S, Jia S, Geoffrey R et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. *N Engl J Med* 2009; 360: 2438–44.

34 Farooq M, Nakai H, Fujimoto A et al. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. *Hum Mutat* 2013; 34: 176–83.

35 Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. *N Engl J Med* 2011; 365: 620–8.

36 Onoufriadis A, Simpson MA, Pink AE et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. *Am J Hum Genet* 2011; 89: 432–7.

37 Rossi-Semerano L, Piram M, Chiaverini C et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. *Pediatrics* 2013; 132: e1043–7.
CPD questions

Learning objective
To demonstrate an understanding of the features and treatment of the commonest SAIDs

Question 1
Which of the following statements regarding treatment of cryopyrin-associated periodic syndromes is true?
(a) There is no effective treatment.
(b) The only treatment on offer is symptomatic relief.
(c) Treatment consists of long-term oral steroids.
(d) Treatment consists of topical steroids.
(e) Treatment consists of interleukin-1 blockade.

Question 2
Which of the following is known to typically exacerbate the rash of cryopyrin-associated periodic syndromes (CAPS)?
(a) Warmth.
(b) Viral infection.
(c) Cold.
(d) Lack of sleep.
(e) Pressure.

Question 3
What is the typical skin manifestation of familial Mediterranean fever (FMF)?
(a) Maculopapular rash localizing to the limbs.
(b) Erysipelas-like erythema between the knee and foot.
(c) Large scaly plaques predominantly on the trunk.
(d) Bullous eruption localizing to sun-exposed sites.
(e) Urticarial lesions over the forearms.

Question 4
Which of the following is associated with untreated familial Mediterranean fever (FMF)?
(a) AA amyloidosis.
(b) Bowel perforation.
(c) Sensorineural hearing loss.
(d) Skeletal deformity.
(e) Malignancy.

Question 5
Which of the following is strongly associated with Schnitzler syndrome (SS)?
(a) Hyperthyroidism.
(b) Gastrointestinal malignancy.
(c) Underlying Tuberculosis.
(d) Plasma cell malignancy.
(e) Lymphoma.

Instructions for answering questions
This learning activity is freely available online at http://www.wileyhealthlearning.com/ced
Users are encouraged to
• Read the article in print or online, paying particular attention to the learning points and any author conflict of interest disclosures
• Reflect on the article
• Register or login online at http://www.wileyhealthlearning.com/ced and answer the CPD questions
• Complete the required evaluation component of the activity

Once the test is passed, you will receive a certificate and the learning activity can be added to your RCP CPD diary as a self-certified entry.

This activity will be available for CPD credit for 2 years following its publication date. At that time, it will be reviewed and potentially updated and extended for an additional period.